Eczema can make a child's life miserable with relentless itching and painful rashes. A fresh look at the research on a newer class of topical creams, called PDE4 inhibitors, offers some encouraging news for families. The analysis, which pooled data from five clinical trials involving nearly 1,900 kids with mild-to-moderate eczema, found that using these creams was linked to significantly better skin clearance and higher odds of treatment success after two and four weeks, compared to using a simple moisturizing base cream. Importantly, the review didn't find a significant difference in overall side effects between the treatments. However, it's crucial to understand what this analysis can and cannot tell us. The results show a strong association, but they report the benefit in relative terms (like 'three times more likely') without giving the absolute numbers. We don't know exactly how many more kids saw real improvement. The authors themselves cautiously conclude the creams 'might be' an effective option, highlighting that more research is needed to fully understand their place in care.
Photo by Pharmacy Images / Unsplash
Could a new cream help kids with eczema find relief faster?
Plain Language Summary
What this means for you:
New eczema creams linked to better skin in kids, with similar side effects to placebo. What this means for you:
New eczema creams linked to better skin in kids, with similar side effects to placebo. View Original Abstract ↓
OBJECTIVE: To compare the clinical efficacy and safety of different topical phosphodiesterase 4 (PDE4) inhibitors for atopic dermatitis (AD) treatment in pediatric patients.
DATA SOURCES: Clinical trials were identified from PubMed, Cochrane Library, EBSCO, Web of Science, and Ovid Medline databases until September 2023.
STUDY SELECTION: Only randomized controlled trials (RCTs) with topical PDE4 inhibitors versus topical vehicle treatment for pediatric patients with mild-to-moderate AD were included. This meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PRISMA) and was registered in PROSPERO. Data were pooled using the random-effects model if I2 >50%.
DATA EXTRACTION: Five RCTs were identified, which included 1877 pediatric patients with mild to moderate AD.
DATA SYNTHESIS: Overall, compared with the topical vehicle control, PDE4 inhibitors were associated with higher response rate in Investigator Global Assessment scores (OR: 3.56, 95% CI: 2.09 to 6.04, P = .005) and increased treatment success rates at weeks 2 (OR: 4.09, 95% CI: 2.32 to 7.21, P < .00001) and weeks 4 (OR: 3.06, 95% CI: 1.52 to 6.18, P = .002). PDE4 inhibitors also associated with higher Eczema Area and Severity Index scores (OR: -4.11, 95% CI: -4.83 to 3.39, P < .00001). There were no significant differences in adverse events (OR: 1.16; 95% CI: 0.93 to 1.44, P = .18) or drug-related adverse events (OR: 1.46, 95% CI: 0.99 to 2.15, P = .05).
CONCLUSIONS: PDE4 inhibitors might be an effective and safe treatment option for pediatric patients with AD.